Beam Therapeutics

ISIN US07373V1052

 | 

WKN A2PY7P

Market cap (in EUR)
2.175 m
Country
Verenigde Staten
Sector
Gezondheidszorg
Dividend yield
0,00%
 

Overview

Description

Beam Therapeutics, Inc. is een biotechnologiebedrijf dat zich bezighoudt met de ontwikkeling van een geïntegreerd platform voor genetische precisiegeneesmiddelen. De pijplijn omvat BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301 en BEAM-201. Het bedrijf werd op 25 januari 2017 opgericht door David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli en J. Keith Joung en heeft zijn hoofdkantoor in Cambridge, MA.
Show more Show less
Gezondheidszorg Biofarmaceutica Andere Biofarmaceutica Verenigde Staten

Financials

Key metrics

Market capitalisation, EUR 2.175 m
EPS, EUR -0,90
P/B ratio 2,0
P/E ratio -
Dividend yield 0,00%

Income statement (2025)

Revenue, EUR 124 m
Net income, EUR -71 m
Profit margin -57,24%

What ETF is Beam Therapeutics in?

There are 4 ETFs which contain Beam Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Beam Therapeutics is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.22%
Equity
United States
Health Care
Biotech
48
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing 0.00%
Equity
World
Social/Environmental
465
Vanguard ESG North America All Cap UCITS ETF (USD) Distributing 0.00%
Equity
North America
Social/Environmental
23
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.04%
Equity
United States
Small Cap
189
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.